FDA Advisory Panel Votes to Loosen Rules on BPC-157, TB-500, and MOTS-C Despite Agency Scientists' Opposition An FDA advisory committee voted narrowly on July 23, 2026, to recommend that compounding pharmacies gain access to several popular peptide compounds, including BPC-157, KPV, TB-500, and MOTS-C, overriding explicit objections from the FDA's own career scientists and sparking an audible gasp in the meeting room when the tally was announced
PCAB (Pharmacy Compounding Accreditation Board) accreditation Third-party signal of quality standards beyond minimum state licensure
The availability of various NAD+ precursors and analogs has enabled researchers to systematically investigate NAD+ function in different cellular contexts and disease models, providing insights into fundamental biological processes and potential research targets
5-Amino-1MQ blocks an enzyme in the body known as NNMT, which is often overactive in fat tissue
Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D
The integration of peptide therapy with conventional orthopedic rehabilitation is another area where coordinated approaches could accelerate timelines
